RESUMO
The paper describes two clinical cases of essential thrombocythemia (ET) complicated by thrombosis in parturients. ET was diagnosed only postpartum when thrombotic complications occurred. Both patients received anagrelid as first-line therapy, as well as Clexane and oral anticoagulants. It is shown that even in younger ET patients with low-risk pregnancies thrombosis and inflammation may be a stimulus to serious thrombotic complications and require special attention.
Assuntos
Fibrinolíticos/uso terapêutico , Quinazolinas/uso terapêutico , Trombocitemia Essencial/complicações , Trombose/complicações , Plaquetas/efeitos dos fármacos , Enoxaparina/administração & dosagem , Enoxaparina/uso terapêutico , Feminino , Fibrinolíticos/administração & dosagem , Humanos , Parto/sangue , Contagem de Plaquetas , Gravidez , Quinazolinas/administração & dosagem , Trombocitemia Essencial/sangue , Trombocitemia Essencial/tratamento farmacológico , Trombose/sangue , Trombose/tratamento farmacológico , Adulto JovemRESUMO
Comparative study of immunological phenotype of lymphoid cells of peripheral blood of patients with chronic lymphoid leukemia (CLL) and immune cytopenia at the treatment with prednisolone and chlorambucil has been carried out. It was shown, that inclusion in the treatment of chlorambucil (chlorambucil + prednisolone) enabled the achievement of remission of immune process at the majority of patients though average duration of remission essentially did not differ. The best clinical result was accompanied by more essential variations of leukemic B-cellular population than during the treatment with prednisolone alone. The reduction of absolute number of lymphocytes in patients with CLL under the treatment with chlorambucil and prednisolone was accompanied by reduction of expression of separate B-cellular antigens of mature cells with minimal signs of their activation. The expediency of a combination of prednisolone with chlorambucil in cases of high leukocytosis and expressed hyperplasia of organs of the limphoid systems.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doenças Autoimunes/tratamento farmacológico , Linfócitos B/imunologia , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Linfócitos T/imunologia , Idoso , Antígenos CD/biossíntese , Antígenos CD/imunologia , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Doenças Autoimunes/complicações , Doenças Autoimunes/imunologia , Linfócitos B/efeitos dos fármacos , Membrana Celular/efeitos dos fármacos , Membrana Celular/imunologia , Clorambucila/administração & dosagem , Clorambucila/uso terapêutico , Feminino , Humanos , Imunofenotipagem , Leucemia Linfocítica Crônica de Células B/complicações , Leucemia Linfocítica Crônica de Células B/imunologia , Masculino , Pessoa de Meia-Idade , Prednisolona/administração & dosagem , Prednisolona/uso terapêutico , Indução de Remissão , Linfócitos T/efeitos dos fármacos , Resultado do TratamentoRESUMO
Efficiency of recombinant activated factor VII (rFVIIa) (NovoSeven) in treatment of patients with idiopathic thrombocytopenic purpura (ITP) complicated with subarachnoid and parenchimatous hemorrhage was shown in the article. The action of NovoSeven in patients with an affected megakaryocytic system depends on the binding of rFVIIa with activated thrombocites and on their surface rFVIIa provides the activation of X factor and thrombin formation. NovoSeven proved to be called a universal hemostatic medication for the idiopathic thrombocytopenic purpura treatment. Taking into account that transfusion of thrombocites concentrate is not recommended for patients with thrombocytopenia of immune origin and after immunoglobulin infusion we need time to see thrombocites number grow so in urgent NovoSeven is a medication of choice to stop bleeding in patients with ITP.
